Home -> Law Blog Directory -> Intellectual Property Law Blogs -> Orange Book Blog: At the Intersection of Patent Law and FDA Law
OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Intellectual Property Law
: Orange Book Blog: At the Intersection of Patent Law and FDA LawFederal Circuit Affirms Preliminary Injunction Against Apotex's Generic Version of Pulmicort Respules
By Aaron Barkoff
ADVERTISEMENTS
AstraZeneca v. Apotex, No. 2009-1381 (Fed. Cir. 2010)
by Andrew W. Williams
On Monday, the Federal Circuit affirmed a preliminary injunction granted by the U.S. District Court for the District of New Jersey barring Apotex from launching a generic version of Pulmicort Respules, a budesonide drug made and sold by AstraZeneca. Apotex gained FDA approval of its generic drug product after filing an ANDA with a section viii statement, asserting that it was not seeking approval for once-daily read more
Full post as published by Orange Book Blog: At the Intersection of Patent Law and FDA Law on November 03, 2010 (boomark / email).
Related Searches
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.

AstraZeneca wins over Teva on Pulmincort in DNJ
Grant of stay while preliminary injunction motion pending abuse of discretion
First Circuit Affirms Preliminary Injunction in Copyright Case
Judge Stark: Motion for Preliminary Injunction GRANTED
Abbott Laboratories v. Sandoz, Inc. (Fed. Cir. 2008) - Part II








